Clinical Trial Supplies Market Size, Share, By Services (Biorepository, Cold Chain Logistics and Distribution, Secondary Packaging and Labelling, and Others), Phases (Phase I, Phase II, Phase III, and Phase IV), Type (Small-Molecule Drugs, Biologic Drugs, and Others), Study Design (Interventional Trials, Observational Trials, and Expanded Access Trials), Application, End-User, and Region - Trends, Analysis, and Forecast till 2035

• By 2035, the clinical trial supplies market is anticipated to reach a valuation of USD 5.7 Billion.
• In 2024, the market’s valuation was at USD 2.8 Billion.
• Target market is developing at a CAGR of 7.2%.

All of the materials required to carry out a clinical study, which is used to assess the safety and efficacy of a novel therapy while abiding by stringent regulatory requirements, including medications, medical equipment, and biological materials are referred to as clinical trial supplies. The increased research and development by biopharmaceutical companies, increasing clinical trials, and the need for new therapies is driving the clinical trial supplies market growth. Moreover, clinical trial supplies have the ability to manage the entire supply chain efficiently, ensures timely delivery of materials to trial sites, helps in accurate labelling, proper storage, and overall streamlined trial operations, ultimately leading to faster study start-up and improved data quality, thereby, further contributing in the market expansion.

Impact of Generative AI on Clinical Trial Supplies Market:

By streamlining data analysis, improving protocol design, simplifying patient recruitment, and facilitating more effective management of clinical trial supplies, generative AI is having a substantial impact on the clinical trial supply chain. This will ultimately result in quicker development times, lower costs, and more accurate research findings, thus stimulating the clinical trial supplies market growth.

Key Drivers of Target Market:

Capability of Clinical Trial Supplies to Store and Streamline Trial Operations is Expected to Foster Market Growth

By guaranteeing data integrity, minimizing delays, cutting costs, and ultimately enabling faster and more efficient clinical trials, which in turn leads to quicker drug development and market entry, clinical trial supplies' capacity to efficiently store medical devices and investigational drugs while also streamlining trial operations is a major factor driving the market's growth. Thus, are opening new clinical trial supplies and logistics depots to distribute treatments to clinical sites and patients globally.

• For instance, in September 2022, Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, announced the opening of a new clinical trial supplies and logistics depot in Suzhou, China. This strategically located facility provided local and international biopharmaceutical customers conducting clinical trials in the region with timely access to supplies and investigative treatments to distribute to clinical sites and patients around the world.

Restraints:

The Complexity of Supply Chain Management is Hindering the Market Growth

The intricacy of supply chain management, which can result in delays, higher expenses, and inefficiencies, is a significant obstacle in the clinical trial supplies market. The challenge is increased by elements, such as demand forecasting, temperature-sensitive logistics, and regulatory compliance.  Patient safety and trial schedules may be impacted by any interruption.

• Counterbalance Statements: Efficiency may be increased by implementing cutting-edge supply chain technology, such as blockchain for traceability and AI-driven forecasting.  By collaborating with expert logistics companies, risks are reduced and compliance is guaranteed.

Opportunities:

Integrating Advanced Technologies with Clinical Trial Supplies is Unlocking Growth Opportunities in the Future

Significant technological advancements are anticipated to impact clinical trial supplies in the future, especially with the integration of digital systems for better tracking, data analysis, and streamlined distribution. This could enable personalized medicine approaches with customized drug delivery systems and increase the efficiency and accuracy of managing investigational drugs throughout the clinical trial process.

• For instance, in February 2024, Revvity Signals, the software and informatics unit of Revvity, had introduced the Signals Clinical solution, a software-as-a-service (SaaS) platform aimed at centralising complete clinical trial data. This end-to-end clinical data science platform was designed to expedite vital trial insights and data-driven decisions to transform the access to and analysis of trial data.

Services, phases, type, study design, application, end-user, and region are the segmentations of clinical trial supplies market.

Services

Based on services, the market is divided into biorepository, cold chain logistics and distribution, secondary packaging and labeling, and others. The cold chain logistics and distribution service is attributed to dominate the market. This is due to the increasing demand for temperature-sensitive drugs such as biologics, gene therapies, and vaccines, which require strict storage and transportation.

Phases

By phases, the market is pigeonholed into phase I, phase II, phase III, and phase IV. The Phase III trials hold the largest clinical trial supplies market share due to the large number of patients involved and the complex logistics. Additionally, these trials are conducted at multiple facilities, generate data on a drug’s safety and effectiveness, and are often randomized and blinded further contributing to the segment’s growth.

• For instance, in December 2024,   Merck, announced topline results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg)] in adults with HIV-1 infection that is virologically suppressed on different antiretroviral therapy regimens [baseline antiretroviral therapy (bART)]; MK-8591A-051 or bictegravir/emtricitabine/tenofovir alafenamidei [BIC/FTC/TAF (50 mg/200 mg/25 mg)]; and MK-8591A-052.

Type

According to type, the market is sub-segmented into small-molecule drugs, biologic drugs, and others. The biologics segment of the clinical trial supplies market is projected to govern the market due to the increased demand for biologics, more research into biosimilar drugs, and more approvals for biologics.

• For instance, in October 2024, Biond Biologics Ltd., a private clinical-stage biopharmaceutical company for the intracellular delivery of biologics announced a clinical trial collaboration and supply agreement with Merck KGaA, to evaluate its immunotherapy agent, a biologic, BND-35 in combination with Merck KGaA, Darmstadt, Germany's anti-EGFR monoclonal antibody cetuximab (Erbitux) in Phase 1 clinical trial for the treatment of patients with unresectable or metastatic solid tumors.

Study Design

On the basis of study design, the market is trifurcated into interventional trials, observational trials, and expanded access trials. The interventional trials segment is ruling the market as it is effective at evaluating new drugs and therapies. Moreover, these trials are often large randomized studies that help minimize confounding variables and increase the reliability of the results.

Application

Based on Application, the market is categorized into oncology, CNS, cardiovascular diseases, infectious diseases, metabolic disorders, and others. The oncology segment is dominating the market due to the rising prevalence of cancer, a significant focus on developing novel cancer treatments, the increasing number of drugs in the oncology R&D pipeline, and the complex clinical trial designs often required for cancer therapies.

• For instance, in January 2025, Kazia Therapeutics Limited an oncology-focused drug development company, announced the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer. This novel treatment combination offered a unique approach to targeting this highly aggressive and treatment-resistant type of breast cancer.

End-User

Under end-user, the market is branched into contract research organizations, pharmaceutical and biotechnology companies, research institutes, and others. The pharmaceutical and biotechnology companies are influencing the market due to its large investments in research and development and infrastructure. Furthermore, increasing number of clinical trials and higher spending on drug development also contribute in the segment’s growth.

• For instance, in October 2024, Amneal Pharmaceuticals, Inc., a global pharmaceutical company, and Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, announced that the companies had entered into a collaboration agreement to enable the efficient development and large-scale supply of a clinical trial portfolio of new weight loss medicines globally.

Region

Geographically, the market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: This is the leading region in the clinical trial supplies market, with an estimated share of approximately 55.1%. This is due to its strong presence of pharmaceutical and biotechnology companies, advanced logistics infrastructure, favorable government initiatives, significant investment on research and development, growing prevalence of chronic diseases, increased healthcare expenditures, and presence of key market players.

• For instance, in April 2024, The US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) had launched a new center for internal and external experts to discuss new methods for designing and conducting clinical drug trials. The center would act as a hub to share lessons learned from its other clinical trial initiatives with the drug development community and was meant to promote clinical trial innovation.

Europe: This is the region with the clinical trial supplies market that grows with the highest CAGR, during the forecast period. This is due to its robust healthcare infrastructure, large patient pools, advanced medical expertise, strict regulatory frameworks, and a high concentration of pharmaceutical and biotechnology companies.

• For instance, in February 2024, Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the biopharmaceutical industry, announced its new facility in Dublin, Ireland, to support global clinical trials. The opening of this depot would expand the Company’s global footprint, increase the efficiency of its worldwide clinical trial supply services, and facilitate future growth.

Clinical Trial Supplies Market Report Scope:

Attribute	Details
Market Size 2025	USD 3 Billion
Projected Market Size 2035	USD 5.7 Billion
CAGR Growth Rate	7.2% (2025-2035)
Base year for estimation	2024
Forecast period	2025 – 2035
Market representation	Revenue in USD Billion & CAGR from 2025 to 2035
Regional scope	North America - U.S. and Canada Europe – Germany, U.K., France, Russia, Italy, Spain, Netherlands, and Rest of Europe Asia Pacific – China, India, Japan, Australia, Indonesia Malaysia, South Korea, and Rest of Asia Pacific Latin America - Brazil, Mexico, Argentina, and Rest of Latin America Middle East & Africa – GCC, Israel, South Africa, and Rest of the Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segmentation:

By Services:

• Biorepository
• Cold Chain Logistics and Distribution
• Secondary Packaging and Labelling
• Others

By Phases:

• Phase I
• Phase II
• Phase III
• Phase IV

By Type:

• Small-Molecule Drugs
• Biologic Drugs
• Others

By Study Design:

• Interventional Trails
• Observational Trials
• Expanded Access Trials

By Application:

• Oncology
• CNS
• Cardiovascular Diseases
• Infectious Diseases
• Metabolic Disorders
• Others

By End-User:

• Contract Research Organizations
• Pharmaceutical and Biotechnology Companies
• Research Institutes
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of the Middle East & Africa

The companies operating in the clinical trial supplies market are Thermo Fisher Scientific Inc., Nuvisan GmbH, IQVIA, Parexel International (MA) Corporation, Clinigen Limited, and others. The key players are adopting strategies such as using AI-driven solutions, new product launches, partnerships between key players, and acquisitions for the diversification of the market.

Clinical Trial Supplies Market Companies:

• Thermo Fisher Scientific Inc.
• Nuvisan GmbH
• Parexel International (MA) Corporation
• Clinigen Limited
• ICON plc
• Proventa International
• Bionical Emas
• KLIFO
• Almac Group
• Biocair
• Movianto
• Catalent, Inc
• Sharp Services, LLC
• IQVIA

View an Additional List of Companies in the Clinical Trial Supplies Market

• In March 2023, Calyx, the eClinical and Regulatory solutions and services provider relied on for solving complex data challenges in clinical research, announced the availability of Calyx Supply Simulation, a clinical trial supply forecasting service available through Calyx's in-house expert statistical design and trial supplies consultants. The service aided sponsors in enhancing clinical trial efficiencies by assessing medication requirements, predicting drug lifespan, and determining optimal buffer stock quantities.
• In January 2025, Ancillare, the global leader in clinical trial supply chain solutions, announced the launch of its state-of-the-art Cold Chain Management services, specifically designed to ensure the safe handling and transport of temperature-sensitive supplies and equipment in clinical trials. Recognizing the critical nature of temperature-sensitive products in clinical research, Ancillare is committed to maintaining precise refrigerated temperatures throughout the entire supply chain.

Analyst View:

The clinical trial supplies market is expanding as a result of clinical trials, research by biopharmaceutical firms, and the need for novel treatments.  Faster start-ups and better data quality result from these supplies' effective supply chain management, which guarantees on-time delivery, precise labeling, appropriate storage, and simplified operations.

More Related Reports

eClinical Solutions Market
Clinical Trial Supply and Logistics Market
Preclinical cro market
Pediatric Clinical Trials Market
Omics-Based Clinical Trials Market

Company Name	Thermo Fisher Scientific Inc.
Headquarter	Waltham, Massachusetts, U.S.
CEO	Mr. Marc N. Casper
Employee Count (2024)	125,000 Employees